Grady, K. L., Hof, K. V., Andrei, A., Shankel, T., Chinnock, R., Miyamoto, S., Ambardekar, A. V., Anderson, A., Addonizio, L., Latif, F., et al
Pediatric Cardiology. 2018;39(2):354-364
Aims:To compare an intervention focussed on increasing heart transplant (HT) knowledge, self management, self-advocacy skills and enhancing support, against usual care in young adult HT recipients transferring to adult care.
Interventions:Participants were randomised to receive either a transition program focussing on increasing HT related knowledge, self-care, self-advocacy skills, and social support, versus usual care.
Participants:88 HT recipients from 6 Children’s Hospitals, ready to transition to the adult program, aged ≥ 18 years.
Outcomes:Measured outcomes included HT knowledge, self-management and self-advocacy, support, immunosuppression, adverse events and adherence.
Follow Up:3 and 6 months.
Dr. Liset Pengel, Centre for Evidence in Transplantation, The Royal College of Surgeons of England.
This report presents baseline data of a pilot RCT that compares a transition programme to adult care with usual care for young adults who had a heart transplant. Eighty-eight patients ≥18 years were recruited from six paediatric heart transplant centres in the US and randomised to a 3-month, 2 phase transition programme or standard transfer of care. Prior to randomisation
medical records data were collected and at the last paediatric clinical visit patients completed self-report instruments. The two intervention groups showed no differences in terms of baseline and clinical characteristics or on any of the self-report instruments. The Heart Transplant Knowledge Questionnaire tested knowledge of medications, appointment keeping, healthy lifestyle, benefits and risks of heart transplantation, and transition to adult care, and showed low scores at baseline. Scores on other questionnaires showed that patients are still developing self-management skills and self-advocacy skills. Follow-up data at 3 and 6 months will show whether the transition programme is successful in improving these outcomes and skills when compared to usual care.
Professor Michael Burch, Great Ormond Street Hospital, London, United Kingdom.
This interesting study investigates young adult heart transplant patients transitioning to adult care. The data shown represents the baseline values and shows that the young adults do not have a good understanding of heart transplantation and their self-advocacy and self-management skills are incomplete. This has implications for all paediatric heart transplant programmes.
Young adult solid organ transplant recipients who transfer from pediatric to adult care experience poor outcomes related to decreased adherence to the medical regimen. Our pilot trial for young adults who had heart transplant (HT) who transfer to adult care tests an intervention focused on increasing HT knowledge, self-management and self-advocacy skills, and enhancing support, as compared to usual care. We report baseline findings between groups regarding (1) patient-level outcomes and (2) components of the intervention. From 3/14 to 9/16, 88 subjects enrolled and randomized to intervention (n = 43) or usual care (n = 45) at six pediatric HT centers. Patient self-report questionnaires and medical records data were collected at baseline, and 3 and 6 months after transfer. For this report, baseline findings (at enrollment and prior to transfer to adult care) were analyzed using Chi-square and t-tests. Level of significance was p < 0.05. Baseline demographics were similar in the intervention and usual care arms: age 21.3 +/- 3.2 vs 21.5 +/- 3.3 years and female 44% vs 49%, respectively. At baseline, there were no differences between intervention and usual care for use of tacrolimus (70 vs 62%); tacrolimus level (mean +/- SD = 6.5 +/- 2.3 ng/ml vs 5.6 +/- 2.3 ng/ml); average of the within patient standard deviation of the baseline mean tacrolimus levels (1.6 vs 1.3); and adherence to the medical regimen [3.6 +/- 0.4 vs 3.5 +/- 0.5 (1 = hardly ever to 4 = all of the time)], respectively. At baseline, both groups had a modest amount of HT knowledge, were learning self-management and self-advocacy, and perceived they were adequately supported. Baseline findings indicate that transitioning HT recipients lack essential knowledge about HT and have incomplete self-management and self-advocacy skills.
Sommerer, C., Brocke, J., Bruckner, T., Schaier, M., Morath, C., Meuer, S., Zeier, M., Giese, T.
Aims:To compare the monitoring of cyclosporine A (CsA) using nuclear factor of activiated T-cells -regulated gene expression (NFAT-RE), versus standard CsA trough level (C0) monitoring.
Interventions:Participants were randomly assigned to either standard monitoring (CsA dose adjusted to target a C0 of 80–150 μg/L), or NFAT-RE (CsA adjusted to target a residual NFAT-RE of 15–30%).
Participants:55 renal allograft recipients from a deceased or living donor ≥6 months prior to study entry, aged ≥18 years with stable renal allograft function, and receiving CsA microemulsion, mycophenolic acid with or without low-dose steroids.
Outcomes:The primary outcome measured was the change in arterial stiffness, assessed by pulse wave velocity. Secondary outcomes included peripheral and central blood pressure, cardiac augmentation index, biopsy-proven acute rejection, graft loss or death, renal function, safety and tolerability.
Follow Up:12 months
Mr Simon Knight, Centre for Evidence in Transplantation, The Royal College of Surgeons of England.
This small but interesting RCT investigates the use of immune monitoring using NFAT-regulated gene expression (NFAT-RE) in stable kidney transplant recipients. All patients received cyclosporine and MMF with/without steroids, and control patients were monitored using standard trough cyclosporine levels. The authors demonstrate a significant improvement in pulse-wave velocity and GFR with NFAT-RE monitoring, with no obvious excess in adverse events
or rejection. The small size of this study means that further evidence would be required to demonstrate safety in terms of rejection and graft survival. It appears, however, that NFAT-RE monitoring may allow minimisation of cyclosporine dose safely in these stable, low risk recipients. It is worth noting that trough cyclosporine levels in the standard monitoring arm increased over the 12-month study period, with a corresponding fall in GFR, which does raise the risk of treatment bias in a non-blinded study such as this.
Professor Ron Shapiro, Kidney/Pancreas Transplantation, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mt. Sinai, USA.
This is an extremely interesting trial of utilizing immunologic monitoring to manage immunosuppression in stable renal transplant recipients. Patients were randomized either to routine PK monitoring (i.e. peak and trough levels) or NFAT-regulated gene expression. Patients randomized to NFAT-regulated gene expression had reduced cardiovascular risk, as assessed by pulse wave velocity, fewer infections, and better renal function than
the control group. This is a very important trial. Most immunosuppression is, at some level, an educated guess about what patients should be receiving, based on a composite of clinical and laboratory factors, but without any real immunologic monitoring data. This trial utilized immunologic monitoring to titrate immunosuppressive drug dosing. Even with a very small number of patients, the authors were able to demonstrate a benefit of immunologic monitoring. The study utilized an immunosuppressive agent, cyclosporine that is used in a very small minority of transplant recipients. This work should be repeated by other centers, with larger numbers of patients, utilizing tacrolimus-based immunosuppression. If the findings from this initial experience are replicated, this could lead to a sea change in how patients are managed after transplantation.
BACKGROUND A new immune monitoring tool which assesses the expression of nuclear factor of activated T-cells (NFAT)-regulated genes measures the functional effects of cyclosporine A. This is the first prospective randomized controlled study to compare standard pharmacokinetic monitoring by cyclosporine trough levels to NFAT-regulated gene expression (NFAT-RE). METHODS Expression of the NFAT-regulated genes was determined by qRT-PCR at cyclosporine trough and peak level. Cardiovascular risk was assessed by change of pulse wave velocity from baseline to month 6. Clinical follow-up was 12 months. RESULTS In total, 55 stable kidney allograft recipients were enrolled. Mean baseline residual NFAT-regulated gene expression was 13.1 +/- 9.1 %. Patients in the NFAT-RE group showed a significant decline in pulse wave velocity from baseline to month 6 versus the standard group (-1.7 +/- 2.0 vs. 0.4 +/- 1.4 m/s, p<0.001). Infections occurred more often in the standard group compared to the immune monitoring group. No opportunistic infections occurred with NFAT-RE monitoring. At 12 months' follow-up, renal function was significantly better with NFAT-RE versus standard monitoring (Nankivell GFR 68.5 +/- 17.4 vs. 57.2 +/- 19.0 ml/min, p=0.009). CONCLUSIONS NFAT-RE as translational immune monitoring tool proved efficacious and safe in individualizing cyclosporine therapy, with the opportunity to reduce the cardiovascular risk and improve long-term renal allograft function.